SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing extreme volatility driven by a massive, supply-constrained short squeeze that has captivated the trading community. Investors are actively debating whether this parabolic move is a sustained mechanical phenomenon controlled by major stakeholders or a high-risk bubble nearing an inevitable and violent exhaustion.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on high volume as investors react to management's comments on production scaling and deepening partnerships within the AI infrastructure ecosystem. The community is actively discussing a perceived 'short squeeze' while dismissing recent negative sentiment as tactical positioning, focusing instead on the company's transition from speculative tech to a scaling supplier.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing intense volatility and social media attention as traders debate whether its recent surge is a sustainable breakout driven by its role in AI data center power infrastructure or a speculative bubble destined for a reversal. The community remains sharply divided, with bulls pointing to the company's strategic partnerships and GaN technology advancements, while bears argue the valuation is detached from current revenue and profitability.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is capturing market attention as investors monitor its progress in autoimmune cell therapy, with the community closely tracking upcoming clinical data readouts and institutional activity. Discussions center on the company's competitive position in the CAR-T space, its cash runway, and high expectations for its pipeline's potential in treating conditions like Myasthenia Gravis and Stiff Person Syndrome.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are intensely debating whether the semiconductor sector is currently in a historic blow-off top or a sustained rally, with many expressing frustration over the persistent daily declines in this inverse ETF despite sector volatility. The community is deeply divided between those capitulating on their positions due to extreme exhaustion and those aggressively averaging down, pinning their hopes on an impending earnings-driven market correction or a significant technical reversal.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors focus on an upcoming poster presentation of its CDK9 inhibitor, SLS009, at the American Association for Cancer Research (AACR) meeting. The community remains deeply divided, with bulls pointing to the drug's potency and potential acquisition value, while bears emphasize frustrations over trial timelines and skepticism regarding the company's historical performance.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch is capturing attention as the community rallies around its unique passive income model, which automatically distributes Solana rewards to holders every six hours. Investors are actively discussing the project's resilience, recent technical developments, and the long-term utility of its reward-generating mechanism.

OpenGradient

OpenGradient is gaining significant momentum as investors rotate capital from other speculative assets, with the community actively highlighting its early-stage potential and high-volume trading activity.

Metropolitan Bank Holding Corp. engages in the provision of banking solutions. It provides a range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and affluent individuals. The company was founded by Mark R. DeFazio on November 24, 1997 and is headquartered in New York, NY.

Metropolitan Bank Holding Corp

Metropolitan Bank Holding Corp is experiencing significant market interest driven by a strategic financial update that has countered recent short-seller narratives, leading to increased volatility. The community is actively debating the bank's fundamental stability, with many investors focusing on insider buying and deposit health while others express concern over lingering regional banking sector risks and potential regulatory exposure.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is trending as investors debate its valuation amid conflicting analyst outlooks, ranging from high-conviction bullish price targets based on record power generation backlogs to cautious downgrades citing competition concerns. The community remains focused on the company's critical role in the AI data center power buildout, often highlighting its status as a foundational long-term holding despite recent intraday price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat...

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - What's Next...

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving Average - Time to Sell?

Crescent Biopharma (NASDAQ:CBIO) Share Price Passes Above 200 Day Moving Average - Should You Sell...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three h...

Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright

HC Wainwright decreased their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are covering the company, Marketbeat.com...

Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - Should You Sell...

Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a report on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating

Guggenheim upgraded Crescent Biopharma to a "strong-buy" rating and set a $35.00 price objective for the company in a research note on Wednesday...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

CBIO
Crescent Biopharma Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CBIO News

CBIOCrescent Biopharma Inc.